Getting answers earlier

One of the promises of the new drug discovery tools is that they will provide answers to key questions about the viability of compounds earlier in the development process, saving time and money.

"The first key inflection point is the decision to commit to an IND program," said Michael Grey, president and CEO of Trega Biosciences Inc. (TRGA, San Diego, Calif.), which is providing in silico screening tools through its NaviCyte Inc. subsidiary.